MICA antibody with affinity maturation and use thereof
Affinity-matured MICA antibodies address the limitations of current immunotherapy by enhancing NK cell recognition and killing of tumor cells through strong binding to the α3 domain, effectively targeting and inhibiting tumor proliferation.
Patent Information
- Application Number
- JP2024074931
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-06
- Filing Date
- 2024-05-02
- Publication Date
- 2024-11-18
- Estimated Expiration
- 2044-05-02
AI Technical Summary
Current immunotherapy treatments, such as PD-1/L1 therapy, have limited efficacy against 'cold tumors' due to low tumor mutation frequency and heterogeneity, and MICA/B expression on tumor cells is downregulated by matrix metalloproteases, allowing tumors to evade NK cell immune monitoring.
Development of affinity-matured MICA antibodies with specific CDR sequences that bind to the α3 domain of MICA, inhibiting shedding and enhancing NK cell recognition and killing of tumor cells.
The affinity-matured MICA antibodies demonstrate stronger binding and tumor-killing activity compared to existing antibodies, effectively targeting and inhibiting tumor cell proliferation with reduced endocytic activity, making them suitable for cancer treatment.
Smart Images

Figure 2024161325000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to the field of antibodies. In particular, the present invention relates to affinity matured MICA antibodies and applications thereof. More particularly, the present invention relates to antibodies or antigen-binding fragments thereof, nucleic acid molecules, expression vectors, methods for preparing antibodies or antigen-binding fragments thereof, recombinant cells, compositions and uses thereof, and drugs and uses thereof. [Background technology]
[0002] Cancer is a serious disease that affects the survival and development of mankind. According to the latest data, there are approximately 19 million new cases of cancer each year worldwide, and approximately 10 million cancer deaths each year, with the incidence and mortality rates showing an upward trend.
[0003] In addition to surgical resection, traditional cancer treatments such as chemotherapy and radiotherapy have strong side effects and are prone to recurrence. In recent years, immunotherapy, including tumor-targeting antibodies, immune checkpoint antibodies, and bispecific antibodies, has become a new hotspot and new hope for anti-cancer.
[0004] In recent years, immunotherapy represented by PD-1 / L1 has shown great potential, but even if the overall response rate of PD-1 / L1 therapy, which is currently the most widely recognized indication, is only 30%, it cannot be ignored that more patients will not benefit. Immune checkpoint molecules are inhibitory molecules expressed on the surface of immune cells, including T, NK, and monocyte-macrophage cells, and after binding to the corresponding ligand, they transmit inhibitory signals into immune cells and inhibit the anti-cancer function of immune cells. Tumors, immune checkpoints that tumors infiltrate lymphocytes have a very large heterogeneity due to ligand expression, so a single type of immune checkpoint inhibitor therapy cannot be applied to all patients, and many patients cannot benefit from it; on the other hand, some patients who have received immune checkpoint inhibitor therapy have tumor recurrence and resistance to the immune checkpoint inhibitor therapy, and the treatment effect cannot be achieved even if the administration is continued; and T cells identify neoantigens, that is, antigens mutated by tumor genes, through the T cell receptor (TCR) on the surface. Some tumors have a low frequency of gene mutation and a small number of neoantigens, and are called "cold tumors". Conventional immune checkpoint inhibitor therapy, such as PD-1 / L1 therapy, achieves anti-cancer purpose by restoring the function of T cells themselves, but in "cold tumors", T cells cannot effectively identify tumors, so immune checkpoint inhibitor therapy is not effective against cold tumors.
[0005] NK cells are another very important anti-cancer immune cell. NK cells and T cells have different recognition mechanisms, and express a series of activating receptors on their surface, which recognize and bind to ligands expressed on the surface of tumors. For example, NK cells recognize and bind to ligands such as MICA and MICB on the surface of tumors through the activating receptor NKG2D, and are activated to kill tumor cells.
[0006] MICA and MICB (major histocompatibility complex type I related chains A and B polypeptides) are proteins encoded by self genes and are not expressed in normal tissues and cells. When cells metastasize to become tumor cells, MICA and MICB are expressed on the surface of tumor cells. NK cells recognize and kill tumors through NKG2D-MICA / B interaction.
[0007] Tumors reduce MICA / B expression on the cell surface through various mechanisms, including matrix metalloproteinase-mediated MICA / B shedding. MICA / B is a type I transmembrane protein, whose extracellular segment contains three domains, α1, α2, and α3, and binds to NKG2D through the α1 and α2 domains. Under the action of matrix metalloproteinases, most of the amino acids in the extracellular segment of MICA / B (including the α1, α2, and part of the α3 domain) are shed from the surface of tumor cells. NKG2D cannot bind the part of the α3 domain that remains on the cell surface, which allows tumors to escape the immune monitoring of NK cells.
[0008] Research has shown that MICA antibodies that bind to the α3 domain can inhibit the shedding of MICA from the tumor surface, and further promote the recognition of NK cells via NKG2D-MICA / B, inhibiting tumor immune evasion. To date, only one MICA monoclonal antibody drug has entered phase I clinical trials (CLN-619), so the development of a targeting MICA monoclonal antibody drug is of great significance to tumor treatment. Summary of the Invention [Problem to be solved by the invention]
[0009] The present invention solves, at least to some extent, at least one of the technical problems existing in the prior art.
[0010] This application is filed based on the following problem and factual findings by the inventors.
[0011] MICA is not expressed in most normal human tissues, but is only expressed at low levels in ovarian, testicular and other tissues, and is widely expressed at high levels in tumor tissues, making MICA a very potential target for tumor therapy. Up to now, there is only one MICA monoclonal antibody in clinical trials, CLN-619, and Genentech has also developed a MICA antibody (1D5V11 in this patent is derived from Genentech's patent). As mentioned above, MICA is a potential therapeutic target, and it is very valuable to develop a monoclonal antibody drug targeting MICA. [Means for solving the problem]
[0012] Thus, in a first aspect, the present invention provides an antibody or antigen-binding fragment thereof, which according to an embodiment of the present invention comprises heavy chain variable region CDR1, CDR2, CDR3 sequences as shown in SEQ ID NOs:1, 2 and 3 or amino acid sequences having at least 80% identity to SEQ ID NOs:1, 2 and 3, respectively, and light chain variable region CDR1, CDR2, CDR3 sequences as shown in SEQ ID NOs:4, 5 and 6 or amino acid sequences having at least 80% identity to SEQ ID NOs:4, 5 and 6, respectively.
[0013] According to an embodiment of the invention, the antibody or antigen-binding fragment is capable of binding to MICA with high affinity.
[0014] According to an embodiment of the present invention, the antibody or antigen-binding fragment may further include at least one of the following additional technical features:
[0015] According to an embodiment of the present invention, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region CDR1 sequence shown in SEQ ID NO:1, a heavy chain variable region CDR2 shown in SEQ ID NO:2, a heavy chain variable region CDR3 shown in SEQ ID NO:3, a light chain variable region CDR1 shown in SEQ ID NO:4, a light chain variable region CDR2 shown in SEQ ID NO:5, and a light chain variable region CDR3 shown in SEQ ID NO:6.
[0016] According to an embodiment of the invention, the antibody or antigen-binding fragment thereof specifically recognizes MICA.
[0017] According to an embodiment of the present invention, the antibody comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:8.
[0018] According to an embodiment of the invention, the antibody is a humanized antibody.
[0019] According to an embodiment of the invention, the antibody or antigen-binding fragment thereof comprises a heavy chain framework region sequence and a light chain framework region sequence, and at least a portion of at least one of the heavy chain framework region sequence and the light chain framework region sequence is derived from at least one of a murine antibody, a human antibody, a primate antibody, or a variant thereof.
[0020] According to an embodiment of the present invention, the antibody or antigen-binding fragment thereof comprises at least one of a heavy chain constant region and a light chain constant region, and at least a portion of at least one of the heavy chain constant region and the light chain constant region is derived from at least one of a human-derived antibody, a primate-derived antibody, and a mouse-derived antibody or a variant thereof.
[0021] According to an embodiment of the present invention, the light chain constant region and the heavy chain constant region are both derived from a mouse IgG1 antibody, an IgG2a antibody or a mutant thereof, or a human IgG1 antibody, an IgG2 antibody, an IgG3 antibody, an IgG4 antibody or a mutant thereof.
[0022] According to an embodiment of the invention, the antibody or antigen-binding fragment thereof is at least one of a single chain antibody, a multimeric antibody, a CDR-grafted antibody, a Fab antibody, and an Fv antibody.
[0023] In a second aspect, the invention provides a nucleic acid molecule, according to an embodiment of the invention, said nucleic acid molecule encoding an antibody or antigen-binding fragment thereof according to the first aspect.
[0024] It is necessary to explain that the nucleic acids referred to in the present specification and claims should be understood by those skilled in the art to include either or both of the complementary strands. For convenience, in most cases, only one strand is shown in the specification and claims, but in reality, the other strand that is complementary to it is also disclosed. Also, the nucleic acid sequences in this application include DNA or RNA formats, and the disclosure of one means the disclosure of the other.
[0025] In a third aspect, the present invention provides an expression vector. According to an embodiment of the present invention, the expression vector carries a nucleic acid molecule according to the second aspect. The expression vector may comprise a selectable control sequence operably linked to the nucleic acid molecule. The control sequence may be one or more control sequences capable of directing expression of the nucleic acid molecule in a host. The expression vector provided in the embodiment of the present invention is capable of efficiently expressing the antibody or antigen-binding fragment in large amounts in a suitable host cell.
[0026] The expression vectors proposed in the embodiments of the present invention can efficiently express the above-mentioned antibodies or antigen-binding fragments thereof in appropriate receptor cells, and the antibodies or antigen-binding fragments thereof designed in the present invention have stronger specificity and higher safety.
[0027] In a fourth aspect, the present invention provides a method for preparing the antibody or antigen-binding fragment thereof, which according to an embodiment of the present invention comprises introducing an expression vector according to the third aspect into a cell, culturing the cell under suitable conditions for the expression and secretion of the protein, and obtaining the antibody or antigen-binding fragment thereof.
[0028] The inventors have discovered that the antibodies or antigen-binding fragments thereof prepared according to the embodiments of the present invention can be cultured more efficiently to produce high-purity antibodies or antigen-binding fragments thereof, and the operation steps are simpler and less costly.
[0029] According to some specific embodiments of the present invention, the cells are not particularly limited and may be prokaryotic or eukaryotic cells.
[0030] According to some specific embodiments of the invention, the cell is a eukaryotic cell.
[0031] According to some specific embodiments of the present invention, the eukaryotic cell is a mammalian cell. According to some specific embodiments of the present invention, when the cell is a eukaryotic cell, such as a mammalian cell, the expression efficiency of the recombinant antibody is high.
[0032] In a fifth aspect of the invention, the invention provides a recombinant cell. According to an embodiment of the invention, the recombinant cell expresses an antibody or antigen-binding fragment thereof according to the first aspect and carries a nucleic acid molecule according to the second aspect or an expression vector according to the third aspect. The recombinant cell is obtained by transfection or transformation with the expression vector. According to some specific embodiments of the invention, the recombinant cell is capable of efficiently expressing the antibody or antigen-binding fragment in large amounts under suitable conditions.
[0033] According to some specific embodiments of the present invention, under appropriate conditions, the recombinant cells can efficiently express large amounts of the antibody or antigen-binding fragment thereof, and the antibody or antigen-binding fragment thereof has stronger specificity, longer half-life and higher efficacy, and can deliver antibody drugs to target cells at lower dosages, thereby achieving effective treatment or prevention of MICA-mediated diseases, with lower toxic side effects and higher safety.
[0034] It should be noted that the recombinant cell of the present invention is not particularly limited and may be a prokaryotic cell, a eukaryotic cell or a bacteriophage. The prokaryotic cell may be Escherichia coli, Bacillus subtilis, Streptococcus or Proteus grotesque, etc. The eukaryotic cell includes fungi such as Pichia pasteur, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Trichoderma, etc., insect cells such as Fallopia oryzae, plant cells such as tobacco, and mammalian cells such as BHK cells, CHO cells, COS cells, myeloma cells, etc. In some embodiments, the recombinant cell according to the present invention is preferably a mammalian cell, including BHK cells, CHO cells, NSO cells or COS cells, and does not include animal germ cells, fertilized eggs or embryonic stem cells.
[0035] It is necessary to explain that the "suitable conditions" described in the specification of this application refer to conditions suitable for the expression of the antibody or antigen-binding fragment described in this application. Those skilled in the art can easily understand that suitable conditions for the expression of an antibody or antigen-binding fragment include, but are not limited to, a suitable transformation or transfection method, suitable transformation or transfection conditions, healthy host cell state, suitable host cell density, suitable cell culture environment, and suitable cell culture time. The "suitable conditions" are not particularly limited, and those skilled in the art can optimize the optimal conditions for the expression of the antibody or antigen-binding fragment according to the specific environment of the laboratory.
[0036] In a sixth aspect, the present invention provides a composition, according to an embodiment of the present invention, the composition comprises an antibody or antigen-binding fragment thereof according to the first aspect, a nucleic acid molecule according to the second aspect, an expression vector according to the third aspect or a recombinant cell according to the fifth aspect.
[0037] As described above, the antibodies or antigen-binding fragments according to some specific embodiments of the present invention can effectively bind to human MICA protein and effectively inhibit the proliferation of tumor cells, and therefore compositions containing the above substances can also effectively bind to human MICA protein and have good effects on preventing and / or treating MICA-mediated diseases, and the type of the composition is not particularly limited and may be a food composition or a drug composition.
[0038] The compositions of the invention may be administered in combination with each other or with one or more other therapeutic compounds, for example, in combination with a chemotherapeutic agent. Thus, the compositions may include a chemotherapeutic agent. The antibodies or antigen-binding fragments thereof, nucleic acid molecules, expression vectors or recombinant cells of the invention may be combined with a second therapeutic agent, exemplary agents of which include, but are not limited to, other agents that inhibit MICA activity (including other antibodies or antigen-binding fragments thereof, peptide inhibitors, small molecule antagonists, etc.) and / or agents that interfere with MICA upstream or downstream signaling.
[0039] In some embodiments, the composition includes combinations that are separated in time and / or space so long as they function together to achieve the objectives of the present invention. For example, the components included in the composition may be administered to a subject as a whole or separately. When the components included in the composition are administered to a subject separately, each component may be administered to the subject simultaneously or sequentially.
[0040] Typically, the antibody or antigen-binding fragment thereof is administered in an effective amount, i.e., an amount sufficient to achieve the desired therapeutic and / or prophylactic effect, e.g., an amount that causes prevention or alleviation of symptoms associated with the disease being treated, e.g., a disease associated with MICA. The effective amount of the composition administered to a subject will depend on the type and severity of the disease and individual characteristics, such as general health, age, sex, weight, and tolerance to drugs, as well as the severity and type of the disease, and the skilled artisan will be able to determine the appropriate dosage depending on these and other factors.
[0041] According to an embodiment of the present invention, after being introduced into a living body, the composition of the present invention can achieve the same therapeutic effect as an antibody or an antigen-binding fragment thereof, a nucleic acid molecule, an expression vector, and a recombinant cell.
[0042] In a seventh aspect of the present invention, the present invention provides the use of the antibody or antigen-binding fragment thereof according to the first aspect, the nucleic acid molecule according to the second aspect, the expression vector according to the third aspect, the recombinant cell according to the fifth aspect, or the composition according to the sixth aspect in the preparation of a medicament. According to an embodiment of the present invention, the medicament is used for preventing and / or treating a MICA-mediated disease. As described above, since the antibody or antigen-binding fragment according to some specific embodiments of the present invention can effectively bind to human MICA protein, a medicament comprising an effective amount of the antibody or antigen-binding fragment or a series of substances thereof can also effectively bind to human MICA protein, and has a good effect on preventing and / or treating MICA-mediated diseases, such as cancer.
[0043] According to an embodiment of the present invention, the MICA mediated disease is cancer.
[0044] According to an embodiment of the present invention, the cancer is at least one of lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, renal cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma and head and neck cancer.
[0045] In an eighth aspect of the present invention, there is provided a medicament, according to an embodiment of the present invention, comprising an antibody or antigen-binding fragment thereof according to the first aspect, a nucleic acid molecule according to the second aspect, an expression vector according to the third aspect, a recombinant cell according to the fifth aspect or a composition according to the sixth aspect, the medicament being used for preventing and / or treating a MICA-mediated disease.
[0046] According to an embodiment of the present invention, the MICA mediated disease is cancer.
[0047] According to an embodiment of the present invention, the disease is at least one of lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, renal cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma and head and neck cancer.
[0048] According to an embodiment of the present invention, the medicament may include a pharma- ceutically acceptable carrier.
[0049] The effective amount of the antibody or antigen-binding fragment according to the present invention may vary depending on the administration pattern, the severity of the disease to be treated, etc. The selection of a preferred effective amount can be determined by one skilled in the art (e.g., by clinical trials) depending on various factors, including, but not limited to, the pharmacokinetic parameters of the active ingredient, such as bioavailability, metabolism, and half-life, the severity of the disease to be treated in the patient, the patient's body weight, the patient's immune status, the route of administration, etc. For example, depending on the exigencies of the treatment situation, the dosage may be divided into several doses per day or the dosage may be proportionally reduced.
[0050] In a ninth aspect of the present invention, the present invention provides the use of an antibody or antigen-binding fragment thereof according to the first aspect, a nucleic acid molecule according to the second aspect, an expression vector according to the third aspect or a recombinant cell according to the fifth aspect in the preparation of a reagent kit. According to an embodiment of the present invention, the reagent kit is used to detect MICA. As described above, since the antibody or antigen-binding fragment according to some specific embodiments of the present invention can effectively bind to human MICA protein, the antibody or antigen-binding fragment can be used to prepare a reagent kit for detecting MICA protein, and the reagent kit can effectively detect human MICA protein qualitatively or quantitatively.
[0051] According to an embodiment of the present invention, the reagent kit can detect MICA more efficiently and accurately, saving time and research costs for clinical treatment.
[0052] In a tenth aspect, the present invention provides a reagent kit, according to an embodiment of the present invention, comprising an antibody or antigen-binding fragment thereof according to the first aspect, a nucleic acid molecule according to the second aspect, an expression vector according to the third aspect or a recombinant cell according to the fifth aspect.
[0053] As described above, the antibody or antigen-binding fragment according to some specific embodiments of the present invention can effectively bind to human MICA protein, and thus a reagent kit including the antibody or antigen-binding fragment can effectively detect human MICA protein qualitatively or quantitatively. The reagent kit according to the present invention can be used as a reagent kit for detecting human MICA protein by utilizing the specific binding between the antibody and the human MICA protein, for example, immunoimprinting, immunoprecipitation, etc. These reagent kits can include any one or more of antagonists, anti-MICA antibodies or drug reference materials, protein purification columns, immunoglobulin affinity purification buffers, cell assay diluents, specifications, literature, etc. Anti-MICA antibodies can be used in different types of diagnostic tests, for example, to detect the presence of various diseases or drugs, toxins, or other proteins in vitro or in vivo, and can be used to test for related diseases, for example, by detecting serum or blood of a subject, and the reagent kit can also be used for scientific research to detect human MICA protein in a specimen. Such related diseases can include MICA-related diseases, for example, cancer. Of course, the antibodies or antigen-binding fragments provided herein can also be used in radioimmunoassays and radioimmunotherapy of the above diseases. In the above application scenarios, the binding molecules can be similarly applied, and will not be described again here.
[0054] According to some specific embodiments of the present invention, the reagent kit may also include a conventional coating solution for detecting MICA.
[0055] In an eleventh aspect of the present invention, the present invention provides a method for treating or preventing a MICA-mediated related disease. According to an embodiment of the present invention, the method comprises administering to a subject at least one of 1) an antibody or antigen-binding fragment according to the first aspect, 2) a nucleic acid molecule according to the second aspect, 3) an expression vector according to the third aspect, 4) a recombinant cell according to the fifth aspect, 5) a composition according to the sixth aspect, and 6) a drug according to the eighth aspect. As described above, the antibody or antigen-binding fragment can bind to human MICA protein and can effectively treat or prevent a MICA-mediated related disease, preferably cancer, so that the method according to the embodiment of the present invention can effectively treat or prevent a MICA-mediated related disease.
[0056] According to an embodiment of the present invention, the cancer includes at least one of lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, renal cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, and head and neck cancer.
[0057] In a twelfth aspect of the present invention, a method for diagnosing MICA-mediated related diseases is provided. According to an embodiment of the present invention, the method includes the steps of: detecting MICA in a specimen using at least one of 1) the antibody or antigen-binding fragment described in the first aspect, 2) the nucleic acid molecule described in the second aspect, 3) the expression vector described in the third aspect, and 4) the recombinant cell described in the fifth aspect; and determining the content of MICA in the specimen based on the result of the detection of MICA. Since the antibody or antigen-binding fragment provided in the present application, or the antibody or antigen-binding fragment expressed by the nucleic acid molecule, expression vector, or recombinant cell can effectively bind to human MICA protein, or the antibody or antigen-binding fragment expressed by the nucleic acid molecule, expression vector, or recombinant cell can effectively bind to MICA, the method described in the present application can be used to effectively detect the content of MICA in a specimen from a test individual, and effectively diagnose MICA-related diseases.
[0058] According to an embodiment of the present invention, the above disease diagnosis method may further include at least one of the following additional technical features:
[0059] According to an embodiment of the present invention, the content of MICA in the sample is equal to or exceeds a minimum threshold value for the presence of the MICA, which is an indication that the sample is derived from a patient suffering from a MICA-related disease, and the minimum threshold value can be determined by comparative analysis and verification of the difference in the content of MICA in the samples of a number of individuals suffering from the MICA-related disease and a number of healthy individuals.
[0060] According to an embodiment of the present invention, the sample comprises at least one of blood, saliva, sweat, tissue, cells, blood, serum, plasma, feces and urine.
[0061] According to an embodiment of the present invention, the MICA-mediated associated disease comprises cancer.
[0062] According to an embodiment of the present invention, the cancer includes at least one of lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, renal cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, and head and neck cancer.
[0063] In a thirteenth aspect of the present invention, a method for staging MICA-mediated related diseases is provided. According to an embodiment of the present invention, MICA is detected in a specimen using at least one of 1) the antibody or antigen-binding fragment according to the first aspect, 2) the nucleic acid molecule according to the second aspect, 3) the expression vector according to the third aspect, and 4) the recombinant cell according to the fifth aspect, and the content of MICA in the specimen is determined based on the result of the detection of MICA. Since the antibody or antigen-binding fragment according to the present application, or the antibody or antigen-binding fragment expressed by the nucleic acid molecule, expression vector, or recombinant cell can effectively bind to human MICA protein, the method according to the present application can effectively detect the content of MICA in a specimen from a test individual and evaluate the stage of MICA-mediated related diseases based on the content of MICA.
[0064] According to an embodiment of the present invention, the above disease staging method may further include at least one of the following additional technical features:
[0065] According to an embodiment of the present invention, the content of MICA in the sample is equal to or greater than the reference level for stage IV tumor disease, the content of MICA in the sample is between the reference levels for stages IV and III tumor disease, the content of MICA in the sample is between the reference levels for stages III and II tumor disease, the content of MICA in the sample is between the reference levels for stages I ... Those skilled in the art will understand that the level of MICA in the case of the above-mentioned stage I, stage II, stage III, stage IV tumors varies depending on the type of tumor, and the stage of the tumor can be determined by comparing the content of MICA in the above-mentioned sample with the reference level of MICA for the corresponding tumor stage, or by comparing the content of MICA in the above-mentioned sample with the content of MICA in samples from individuals or populations of known disease stages. The value of the reference level of the above-mentioned stage I, stage II, stage III, stage IV tumors can be determined by comparative analysis and verification of the difference in the content of MICA in the samples of a number of individuals suffering from the above-mentioned MICA-related disease and a number of healthy individuals.
[0066] According to an embodiment of the present invention, the sample comprises at least one of blood, saliva, sweat, tissue, cells, blood, serum, plasma, feces and urine.
[0067] According to an embodiment of the present invention, the MICA-mediated associated disease comprises cancer.
[0068] According to an embodiment of the present invention, the cancer includes at least one of lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, renal cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, and head and neck cancer.
[0069] In a fourteenth aspect of the present invention, there is provided a method for evaluating the prognosis of a MICA-mediated related disease, which, according to an embodiment of the present invention, comprises the steps of detecting MICA in a subject using at least one of 1) the antibody or antigen-binding fragment according to the first aspect, 2) the nucleic acid molecule according to the second aspect, 3) the expression vector according to the third aspect, and 4) the recombinant cell according to the fifth aspect, and determining the content of MICA in the subject based on the result of the detection of MICA. As described above, the content of MICA has an important effect on cancer. After treating an individual suffering from a related disease, the content of MICA in the tissues or excretions, such as peripheral blood and urinary fluid, can be monitored to effectively evaluate the prognosis of the disease, for example by comparing the content of MICA in the subject's body before and after treatment, or by comparing the content of MICA in the subject's body after treatment with the MICA level in normal or diseased individuals. Since the antibodies or antigen-binding fragments presented in the present application, or the antibodies or antigen-binding fragments expressed by nucleic acid molecules, expression vectors, and recombinant cells can all effectively bind to human MICA protein, the method described in the present application can be used to effectively detect the content of MICA in a sample derived from a test individual, and the prognosis of the related disease caused by MICA can be evaluated based on the content of MICA.
[0070] According to an embodiment of the present invention, the above-mentioned method for evaluating disease prognosis may further include at least one of the following additional technical features:
[0071] According to an embodiment of the invention, the subject is from a patient suffering from a MICA-mediated related disease, either pre- or post-treatment.
[0072] According to an embodiment of the present invention, the sample comprises at least one of blood, saliva, sweat, tissue, cells, blood, serum, plasma, feces and urine.
[0073] According to an embodiment of the present invention, the prognostic effect of a MICA-mediated related disease is determined based on the content of MICA in a sample of a patient suffering from a MICA-mediated related disease before or after the treatment.
[0074] According to an embodiment of the present invention, the MICA-mediated associated disease comprises cancer.
[0075] According to an embodiment of the present invention, the cancer includes at least one of lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, renal cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, and head and neck cancer.
[0076] In a fifteenth aspect of the present invention, the present invention provides use of the antibody or antigen-binding fragment according to the first aspect, the nucleic acid molecule according to the second aspect, the expression vector according to the third aspect, the recombinant cell according to the fifth aspect, the composition according to the sixth aspect, or the drug according to the eighth aspect of the present invention in treating or preventing a MICA-mediated related disease. As described above, the antibody or antigen-binding fragment can effectively bind to human MICA protein, and can effectively treat or prevent a MICA-mediated related disease.
[0077] According to an embodiment of the present invention, the above use may further include at least one of the following additional technical features:
[0078] According to an embodiment of the present invention, the MICA-mediated associated disease comprises cancer.
[0079] According to an embodiment of the present invention, the cancer includes at least one of lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, renal cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, and head and neck cancer.
[0080] In a sixteenth aspect of the present invention, the present invention provides the use of the antibody or antigen-binding fragment according to the first aspect, the nucleic acid molecule according to the second aspect, the expression vector according to the third aspect, or the recombinant cell according to the fifth aspect in the diagnosis, staging, or prognosis assessment of a MICA-mediated related disease. As described above, the antibody or antigen-binding fragment provided in the present application, or the antibody or antigen-binding fragment expressed by the nucleic acid molecule, expression vector, or recombinant cell can effectively bind to human MICA protein, and therefore the method described in the present application can be used to effectively detect the content of MICA in a sample derived from a test individual, and to effectively diagnose, stage, and prognosis assessment of a MICA-mediated related disease.
[0081] According to an embodiment of the present invention, the above use may further include at least one of the following additional technical features:
[0082] According to an embodiment of the present invention, the MICA-mediated associated disease comprises cancer.
[0083] According to an embodiment of the present invention, the cancer includes at least one of lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, renal cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, and head and neck cancer.
[0084] A "subject" or "individual" in the context of the present invention refers generally to a mammal, such as a primate and / or rodent, particularly a human, monkey or mouse. Effect of the Invention
[0085] The beneficial effects of the present invention are as follows: 1) The affinity matured antibody h5A1002 obtained in the present invention has stronger binding activity than the parent antibody h5A1 and the alloantibody CLN-619 (Cullinan, in Phase I clinical stage). 2) The affinity-matured antibody h5A1002 obtained in the present invention has stronger activity in promoting tumor killing by PBMCs (human peripheral blood mononuclear cells) than the parent antibody h5A1 and the allogeneic antibody CLN-619 (Cullinan, in phase I clinical stage). 3) The affinity-matured antibody h5A1002 obtained in the present invention has weaker endocytosis activity than the homologous antibody CLN-619 (Cullinan, in Phase I clinical trial), and has better drug discovery potential as a monoclonal antibody and secondary antibody. [Brief description of the drawings]
[0086] The above and / or additional aspects and advantages of the present invention will become apparent and be readily understood from the following detailed description of the embodiments in conjunction with the drawings. [Figure 1] FIG. 1 shows SPR results of affinity measurement between the parent humanized antibody h5A1 antibody according to an embodiment of the present invention and the MICA protein. [Diagram 2] FIG. 13 shows SPR results of affinity measurement between h5A1002 antibody, an affinity-matured antibody according to an embodiment of the present invention, and MICA protein. [Diagram 3] FIG. 1 shows the results of ELISA binding between parent antibody h5A1 and affinity matured antibody h5A1002 and MICA*002-Fc protein according to an embodiment of the present invention. [Figure 4] FIG. 1 shows the results of ELISA binding between parent antibody h5A1 and affinity matured antibody h5A1002 and MICA*005-Fc protein according to an embodiment of the present invention. [Diagram 5] FIG. 1 shows the results of ELISA binding between parent antibody h5A1 and affinity matured antibody h5A1002 according to an embodiment of the present invention and MICA*008-Fc protein. [Figure 6] FIG. 1 shows the results of ELISA binding between parent antibody h5A1 and affinity matured antibody h5A1002 and MICA*004-Fc protein according to an embodiment of the present invention. [Figure 7] FIG. 1 shows the results of ELISA binding between parent antibody h5A1 and affinity matured antibody h5A1002 and MICB*001-Fc protein according to an embodiment of the present invention. [Figure 8] FIG. 1 shows the results of ELISA binding between parent antibody h5A1 and affinity matured antibody h5A1002 and MICB*005-Fc protein according to an embodiment of the present invention. [Figure 9] FIG. 1 shows flow cytometry results of binding of parent antibody h5A1 and affinity matured antibody h5A1002 according to an embodiment of the present invention to human melanoma A-375 cells. [Figure 10] FIG. 1 shows flow cytometry results of binding of parent antibody h5A1 and affinity matured antibody h5A1002 according to an embodiment of the present invention to human rectal cancer HCT-15 cells. [Figure 11] FIG. 1 shows the results of ELISA binding of affinity matured antibody h5A1002 according to an embodiment of the present invention, alloantibodies CLN-619 (Cullinan) and 1D5V11 (Genentech) to MICA*002-Fc protein. [Figure 12] FIG. 1 shows the results of ELISA binding of affinity matured antibody h5A1002 according to an embodiment of the present invention, alloantibodies CLN-619 (Cullinan) and 1D5V11 (Genentech) to MICA*005-Fc protein. [Figure 13] FIG. 1 shows the results of ELISA binding of affinity matured antibody h5A1002 according to an embodiment of the present invention, alloantibodies CLN-619 (Cullinan) and 1D5V11 (Genentech) to MICA*008-Fc protein. [Figure 14] FIG. 1 shows the results of ELISA binding of affinity matured antibody h5A1002 according to an embodiment of the present invention, alloantibodies CLN-619 (Cullinan) and 1D5V11 (Genentech) to MICA*004-Fc protein. [Figure 15] FIG. 1 shows the results of ELISA binding of affinity matured antibody h5A1002 according to an embodiment of the present invention, alloantibodies CLN-619 (Cullinan) and 1D5V11 (Genentech) to MICB*001-Fc protein. [Figure 16]FIG. 1 shows the results of ELISA binding of affinity matured antibody h5A1002 according to an embodiment of the present invention, alloantibodies CLN-619 (Cullinan) and 1D5V11 (Genentech) to MICB*005-Fc protein. [Figure 17] FIG. 1 shows flow cytometry results of binding of affinity matured antibody h5A1002 according to an embodiment of the present invention, alloantibodies CLN-619 (Cullinan) and 1D5V11 (Genentech) to human melanoma A-375 cells. [Figure 18] FIG. 1 shows flow cytometry results of binding of affinity matured antibody h5A1002 according to an embodiment of the present invention, alloantibodies CLN-619 (Cullinan) and 1D5V11 (Genentech) to human non-small cell lung cancer A549 cells. [Figure 19] FIG. 1 shows flow cytometry results of binding of affinity matured antibody h5A1002 according to an embodiment of the present invention, alloantibodies CLN-619 (Cullinan) and 1D5V11 (Genentech) to human rectal cancer HCT-15 cells. [Figure 20] FIG. 1 shows flow cytometry results of binding of affinity matured antibody h5A1002 according to an embodiment of the present invention, alloantibodies CLN-619 (Cullinan) and 1D5V11 (Genentech) to human breast cancer MDA-MB-231 cells. [Figure 21] This is a flow cytometry result diagram showing the competitive binding of affinity matured antibody h5A1002 according to an embodiment of the present invention, allogeneic antibodies CLN-619 (Cullinan), 1D5V11 (Genentech), and h5A1002-Biotin antibody to human rectal cancer HCT-15 cells. [Figure 22] FIG. 1 shows flow cytometry results of affinity matured antibody h5A1002 according to an embodiment of the present invention, and alloantibodies CLN-619 (Cullinan) and 1D5V11 (Genentech) being endocytosed by human breast cancer MDA-MB-231 cells. [Diagram 23]FIG. 1 shows the results of affinity matured antibody h5A1002 according to an embodiment of the present invention promoting killing of human melanoma A-375 cells by PBMCs. [Figure 24] This shows the results of affinity matured antibody h5A1002 according to an embodiment of the present invention, and alloantibodies CLN-619 (Cullinan) and 1D5V11 (Genentech) promoting the killing of human rectal cancer HCT-15 cells by PBMCs. [Diagram 25] This shows the results of affinity matured antibody h5A1002 according to an embodiment of the present invention, and allogeneic antibodies CLN-619 (Cullinan) and 1D5V11 (Genentech) promoting killing of human melanoma A-375 cells by PBMCs. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0087] Hereinafter, the present invention will be described in detail with reference to the examples. The examples described below are merely illustrative and are intended to illustrate the present invention, and should not be construed as limiting the present invention.
[0088] It is necessary to clarify that the terms "first" and "second" are used for descriptive purposes only and cannot be understood as expressing or implying the relative importance or number of technical features being presented. Thus, a feature defined by "first" or "second" can explicitly or implicitly include one or more of said features. In the description of the present invention, "plurality" means two or more than two, unless otherwise limited.
[0089] In this specification, the terms "including" and "comprises" are non-limiting expressions and include the contents shown in the present invention but do not exclude the contents of other aspects.
[0090] As used herein, the terms "selectably," "selectable," or "selectable" generally mean that an event or circumstance described below may occur, but does not necessarily occur, and the description includes cases where the event or circumstance occurs and cases where the event or circumstance does not occur.
[0091] In order to make the present invention easier to understand, some technical and scientific terms are specifically defined below. Unless expressly defined herein, all other technical and scientific terms used herein have the meaning commonly understood by those skilled in the art to which the present invention belongs. The abbreviations of amino acid residues are the standard three-letter and / or one-letter codes for one of the 20 common L-amino acids used in the art.
[0092] The antibody or antigen-binding fragment according to the present invention is usually prepared by a method of biosynthesis. According to the nucleotide sequence according to the present invention, a person skilled in the art can easily prepare the coding nucleic acid of the present invention by various known methods. These methods include, but are not limited to, PCR, DNA artificial synthesis, etc., and specific methods can be referred to J. Sambrook, "Molecular Cloning Experimental Guide". In one embodiment of the present invention, the coding nucleic acid sequence of the present invention can be constructed by a method of synthesizing a nucleotide sequence stepwise and extending it by further PCR. The antibody or antigen fragment is numbered and defined using the Kabat numbering system.
[0093] As used herein, the term "monoclonal antibody" refers to an antibody having a single antigen-binding site.
[0094] As used herein, the term "polyclonal antibody" refers to an antibody having two or more different antigen-binding sites.
[0095] As used herein, the term "mutant" or "variant" can be meant to include molecules that have undergone mutations involving one or more nucleotides or amino acids relative to any naturally occurring or engineered molecule.
[0096] The term "complementarity determining region" or "CDR" or "CDR sequence" refers to the amino acid sequence in an antibody responsible for antigen binding, e.g., typically amino acid residues 23-34 (L1), 50-56 (L2), and 89-97 (L3) in the light chain variable region, and 31-35B (H1), 50-65 (H2), and 95-102 (H3) in the heavy chain variable region (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)), and / or "highly variable" (e.g., amino acid residues about 26-32 (LI), 50-52 (L2), and 91-96 (L3) in the light chain variable region, and about 26-32 (H1), 53-55 (H2), and 96-101 (H3) in the heavy chain variable region (Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)).
[0097] As used herein, "operably connected" means connecting a foreign gene to a carrier, and a control element in the carrier, such as a transcription control sequence or a translation control sequence, can function to regulate the transcription and translation of the desired foreign gene. When connecting the nucleic acid molecule to the carrier, the nucleic acid molecule can be directly or indirectly connected to a control element on the carrier, and these control elements can control the translation and expression of the nucleic acid molecule. Of course, these control elements can be derived directly from the carrier itself or can be exogenous, i.e., they do not have to be derived from the carrier itself. As will be understood by those skilled in the art, nucleic acid molecules for encoding antibodies or antigen-binding fragments can be inserted independently into different carriers, and are often inserted into the same carrier. A typical carrier can be, for example, a plasmid, a bacteriophage, etc., such as Plasmid-X plasmid.
[0098] As used herein, the terms "identity," "homology," or "similarity," when used to describe an amino acid sequence or a nucleic acid sequence relative to a reference sequence, are used in the usual manner to determine the percentage of identical amino acids or nucleotides between two amino acid or nucleic acid sequences, and are described, for example, in Ausubel et al., Eds. (1995), Current Protocols in Molecular Biology, Chapter 19 (Greene Publishing and Wiley-Interscience, New York); and in the ALIGN program (Dayhoff (1978), Atlas of Protein Sequence and Structure 5:Suppl.3 (National Biomedical Research Foundation, Washington, DC. Examples of algorithms for determining matched and measured sequence identity include the homology matching algorithm of Needleman et al. (1970) J. Mol. Biol. 48:443, the local homology algorithm of Smith et al. (1981) Adv. Appl. Math. 2:482, the similarity search method of Pearson et al. (1988) Proc. Natl. Acad. Sci. 85:2444, the Smith-Waterman algorithm (Meth. Mol. Biol. 70:173-187 (1997)), and the BLASTP, BLASTN, and BLASTX algorithms (Altschul et al. (1990) J. Mol. Biol. 215:403-410).Computer programs utilizing these algorithms can also be obtained, and include, but are not limited to, ALIGN or Megalign (DNASTAR) software, or WU-BLAST-2 (Altschul et al., Meth. Enzym., 266:460-480 (1996)), or GAP, BESTFIT, BLAST Altschul, FASTA and TFASTA, among others, available from the Genetics Computing Group (GCG) pack, version 8, Madison, Wisconsin, USA, and CLUSTAL in the PC / Gene program provided by Intelligenetics, Mountain View, California.
[0099] Without substantially affecting the antibody activity (preserving at least 95% activity), the skilled artisan may replace, add and / or delete one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more) amino acids in the sequences of the invention to obtain variants of the sequences of said antibodies or functional fragments thereof, which are considered to be included within the scope of protection of the present invention, such as replacing amino acids with similarity in the variable regions. Said variant sequences of the present invention have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity (or homology) with the reference sequence. Identity of the sequences described in the present invention can be measured with sequence analysis software, for example using the computer program BLAST with default parameters, in particular BLASTP or TBLASTN. All amino acid sequences described in this invention are shown from the N-terminus to the C-terminus.
[0100] As mentioned above, the monoclonal antibodies of the present invention may be full length antibodies or may include only functional fragments thereof (e.g., Fab, F(ab')2 or scFv fragments) or may be modified to affect function. The present invention includes anti-MICA antibodies with modified glycosylation modes. In some applications, it may be useful to modify to remove undesired glycosylation sites or the antibody may lack fucoidan moieties on the oligosaccharide chain, e.g., enhancing antibody-dependent cellular cytotoxicity (ADCC) function. In some other applications, galactosylation modifications may be made to alter complement-dependent cytotoxicity (CDC).
[0101] As used herein, the term "full-length antibody" refers to a tetrapeptide chain structure in which two identical light chains and two identical heavy chains are connected by interchain disulfide bonds, such as immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin M (IgM), immunoglobulin D (IgD), or immunoglobulin E (IgE). Immunoglobulins of the same type can also be divided into different subclasses, such as IgG1, IgG2, IgG3, and IgG4, depending on their amino acid composition. Immunoglobulin light chains are divided into κ chains and λ chains depending on the constant region.
[0102] The term "functional fragment" as used herein refers in particular to antibody fragments such as CDR-grafted antibodies, Fab, Fab', F(ab')2, Fv or scFv, nanobodies, or any fragment that can be chemically modified or introduced into liposomes to increase its half-lifetime, e.g., by adding poly-alkylene glycol such as polyethylene glycol ("pegylated, PEGylated") (referred to as pegylated fragments of Fv-PEG, scFv-PEG, Fab-PEG, F(ab')2-PEG or Fab'-PEG) ("PEG" is polyethylene glycol), and the fragment has MICA binding activity. Preferably, the functional fragment consists of or comprises a subsequence of the heavy or light chain variable region of the antibody from which it is derived, the subsequence being sufficient to retain a binding specificity similar to that of the antibody from which it is derived and sufficient affinity, preferably at least equal to 1 / 100, and in a more preferred manner at least equal to 1 / 10, of the affinity of the antibody from which it is derived, for MICA. Such functional fragments contain at least 3 amino acids, and preferably contain 5, 10, 15, 25, 50 and 100 contiguous amino acids of the antibody sequence from which it is derived.
[0103] In the present invention, unless stated to the contrary, the term "antigen-binding fragment" as used generally refers to an antigen-binding antibody fragment and may include a portion of an intact antibody, typically the antigen-binding or variable region, including, by way of example, CDR-grafted antibodies, Fab, Fab, F(ab')2, Fv or scFv, nanobodies, etc.
[0104] As used herein, the term "CDR-grafted antibody" refers to the transplantation of the CDRs of a monoclonal antibody of one species into the variable region of an antibody of another species. For example, the CDRs of a mouse-derived monoclonal antibody can be transplanted into the variable region of a human-derived antibody, replacing the human-derived antibody CDRs, allowing the human-derived antibody to acquire the antigen-binding specificity of the mouse-derived monoclonal antibody while simultaneously reducing its heterogeneity.
[0105] As used herein, the term "Fab antibody" or "Fab" generally refers to an antibody that contains only a Fab molecule, consisting of the VH and CH1 of the heavy chain and an intact light chain, with the light and heavy chains connected via a single disulfide bond.
[0106] As used herein, the term "nanobody" (single domain antibody or VHH antibody) was originally described as an antigen-binding immunoglobulin (variable) domain of a "heavy chain antibody" (i.e., an antibody lacking light chains) (Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R.: "Naturally occurring antibodies devoid of light chains"; Nature 363, 446-448 (1993)), which contains only a heavy chain variable region (VH) and the usual CH2 and CH3 regions and specifically binds to an antigen via the heavy chain variable region.
[0107] As used herein, the term "Fv antibody" generally refers to an antibody in which only the light chain variable region (VL) and heavy chain variable region (VH) are non-covalently connected, and is the minimum functional fragment of an antibody molecule that retains an intact antigen-binding site.
[0108] As used herein, the term "single chain antibody" or "scFv" refers to a fragment in which the antibody heavy and light chain variable regions are connected by a short peptide.
[0109] As used herein, the term "effective amount" or "effective dosage" refers to an amount that can produce a function or activity in humans and / or animals and that is tolerated by humans and / or animals.
[0110] As used herein, a "pharmaceutically acceptable" ingredient is a substance that may be administered to humans and / or mammals without undue adverse side effects (toxicity, irritation, and allergic reactions), i.e., with a reasonable benefit / risk ratio. The term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent and includes various excipients and diluents.
[0111] The medicament of the present invention comprises a safe and effective amount of the active ingredient of the present invention and a pharma- ceutically acceptable carrier. Such carriers include (but are not limited to) saline, buffer, glucose, water, glycerin, ethanol, and combinations thereof. In general, the drug formulation should be compatible with the mode of administration, which may be oral, nasal, intradermal, subcutaneous, intramuscular, intravenous, or intraperitoneal, and the dosage form of the medicament of the present invention may be an injection, oral preparation (tablet, capsule, oral liquid), transdermal, or sustained release agent. For example, an aqueous solution containing physiological saline or glucose or other auxiliary agents is prepared by a conventional method. The medicament is suitable for manufacture under sterile conditions. The antibody or antigen-binding fragment may be administered by intravenous infusion or injection, or intramuscular or subcutaneous injection.
[0112] In a preferred embodiment of the present invention, the antibody can be humanized to further enhance the bioacceptance of the antibody, i.e., the antibody is a chimeric antibody or a humanized antibody. The term "chimeric antibody" refers to a recombinant antibody in which the amino acid sequence of the constant region of a monoclonal antibody from a certain species (e.g., mouse) is replaced with the constant region of an antibody from another species (e.g., human) using recombinant DNA technology. The term "humanized antibody" refers to a recombinant antibody in which all of the constant region and non-CDR (Fv frame region (FR)) amino acid sequences of the variable region of a monoclonal antibody from a certain species (e.g., mouse) are replaced with the constant region and non-CDR amino acid sequences of the variable region of an antibody from another species (e.g., human) using recombinant DNA technology. That is, when the constant region of an antibody is humanized, it is called a chimeric antibody, and when all of the non-CDR amino acid sequences of the constant region and variable region are humanized, it is called a humanized antibody. The humanization method can be performed with reference to conventional antibody processing techniques, and will not be described again here.
[0113] In the present specification, antibody affinity maturation as described in the present invention refers to the immune functional state in which a living body is normally present. In humoral immunity, the average affinity of antibodies in a second response is higher than that in a first immune response, and this phenomenon is called antibody affinity maturation. This functional state of a living body is the result of long-term evolution and continuous adaptation to the external environment, and is of great significance in maintaining biological defense and autoimmune monitoring. The present invention is a process of obtaining an antibody with significantly improved affinity by using an in vitro antibody affinity maturation technique, specifically, by using a molecular biology technique to mutate the CDR amino acids of an antibody and screening the mutated antibody bank.
[0114] The amino acid or nucleic acid sequences relevant to the present invention are detailed in Table 1.
[0115] [Table 1] TIFF2024161325000003.tif246170TIFF2024161325000004.tif246170TIFF20241613250 00005.tif246170TIFF2024161325000006.tif246170TIFF2024161325000007.tif216170
[0116] The following examples of the present invention are described in detail. The following examples are merely examples and are for the purpose of explaining the present invention, and should not be understood as limiting the present invention. If no specific techniques or conditions are shown in the examples, they should be carried out according to the techniques or conditions described in the literature of the field or according to the product specifications. If no manufacturer is shown for the reagents or equipment used, they are conventional products that can be purchased commercially.
[0117] Example 1: Antibody Production
[0118] The specific experimental procedures for antibody production are as follows: (1) ExpiCHO cells (purchased from Thermo Fisher) were cultured in ExpiCHO Expression Medium (purchased from Thermo Fisher) at a cell concentration of 6 × 10 6 / mL to obtain the ExpiCHO cell solution. (2) Put the pcDNA3.4 carrier (synthesized by Nanjing Jinsirui) containing the antibody heavy chain and the antibody light chain into 2mL of OptiSFM medium (purchased from Thermo Fisher) at a ratio of 1:1 to obtain solution A. (3) Put 160μL of ExpiFectamineCHO transfection reagent (purchased from Thermo Fisher) into 2mL of OptiSFM medium (purchased from Thermo Fisher) to obtain solution B. (4) Next, mix solution A and solution B to obtain the transfection mixture, and add all the transfection mixture to 50mL of ExpiCHO cell solution within 5 minutes. (5) After culturing at 37℃ under 5% CO2 conditions for 1 day, add 8mL of Feed and 300μL of Enhancer (purchased from Thermo Fisher), and after culturing at 32℃ under 5% CO2 conditions for 9 days, obtain the culture supernatant, and add 8mL of Feed on the 5th day. (6) The parent humanized antibody h5A1 antibody is obtained by affinity purification from the culture supernatant using a Protein A purification column (purchased from Nabi).
[0119] Example 2: Antibody Affinity Maturation
[0120] During affinity maturation of natural antibodies, somatic hypermutation is mainly concentrated in the CDR region. By performing single-point saturation mutations at each site of the CDR region in vitro, sufficient mutation diversity can be obtained without destroying the protein structure, and this route can achieve the most similar in vitro reproduction of the in vivo somatic hypermutation of natural antibodies.
[0121] A single-point saturation mutation is performed on each amino acid site in the CDR region to construct a single-point saturation mutation plasmid library that is unbiased to the parent antibody. ELISA is used to screen for mutation sites that specifically bind to the antigen and enhance it, and further combinations of these sites are screened to obtain candidate antibody mutation sequences.
[0122] According to this technical route, the parent humanized antibody h5A1 (prepared by the method in Example 1, the heavy chain variable region SEQ ID NO:9 and the light chain variable region SEQ ID NO:10 from Patent CN114369162A) is affinity matured to obtain the high affinity MICA monoclonal antibody h5A1002 (prepared by the method in Example 1), which has the sequence of the heavy chain variable region (SEQ ID NO:7) and the light chain variable region (SEQ ID NO:8). The comparison of the CDR sequences of the parent humanized antibody h5A1 and the affinity matured antibody h5A1002 is shown in Table 2.
[0123] [Table 2]
[0124] Example 3: Antibody affinity detection
[0125] Biacore is a method for analyzing biomolecular interactions based on the optical surface plasmon resonance (SPR) principle. It not only detects the specific binding between antigens and antibodies, but also obtains data that are extremely important in drug research and development, such as the intermolecular binding rate constant (Ka), dissociation rate constant (Kd), and equilibrium dissociation constant (KD), and thereby calculates the affinity of antibodies.
[0126] In the Biacore 8K (Cytiva) system, the antibody is diluted to 10 μg / mL in the working buffer (HBS-EP) and coupled to a protein A (Cytiva, 29127556) chip at a flow rate of 10 μL / min. The kinetics and affinity data of antigen-antibody binding are detected at a flow rate of 30 μL / min, with the given binding time of 120 s and dissociation time of 800 s.
[0127] The kinetics and affinity data of the parent antibody h5A1 and the affinity matured antibody h5A1002 binding to MICA were obtained, and the results are shown in Table 3. Compared with the parent antibody h5A1, the affinity of the affinity matured antibody h5A1002 to MICA was significantly improved by 39-fold.
[0128] [Table 3]
[0129] Note: Ka indicates the binding rate constant (the larger the value, the stronger the affinity), Kd indicates the dissociation rate constant (the smaller the value, the stronger the affinity), reflecting the affinity of the compound for the target, and KD indicates Kd / Ka, which is the equilibrium dissociation constant (affinity constant), and the smaller the KD, the less dissociation and the stronger the affinity.
[0130] Example 4: MICA antibody ELISA binding experiments
[0131] (1) ELISA is used to detect the binding properties of parent antibody h5A1, affinity matured antibody h5A1002, and the α3 domains of MICA and MICB. The inventors coated the obtained various MICA and MICB variant extracellular domain α3 domain (MICA-002, 005, 008, 004, MICB-001, 005 variant α3 domain) Fc fusion proteins on a 96-well plate, and the signal intensity after antibody addition is used to judge the binding properties of the antibody with MICA and MICB.
[0132] The fusion protein (produced in our laboratory; MICA002α3-Fc amino acid sequence is shown in SEQ ID NO:22, MICA005α3-Fc amino acid sequence is shown in SEQ ID NO:24, MICA008α3-Fc amino acid sequence is shown in SEQ ID NO:25, MICA004α3-Fc amino acid sequence is shown in SEQ ID NO:23, MICB001α3-Fc amino acid sequence is shown in SEQ ID NO:26, and MICB005α3-Fc amino acid sequence is shown in SEQ ID NO:27) is diluted to 1 μg / ml with PBS buffer and added to a 96-well plate in a volume of 100 μL / well and left at 4° C. overnight. The PBS buffer in the 96-well plate is aspirated and removed, and the plate is washed six times with PBST (i.e., PBS with pH 7.2 and 0.1% by volume Tween 20) buffer, and then 200 μL / well of PBS containing 10% BSA is added, and the plate is closed by incubating at 37 ° C for 2 h. The blocking solution is removed, and the plate is washed six times with PBST, and then 100 μL / well of h5A1 antibody (heavy chain sequence SEQ ID NO: 11 and light chain sequence SEQ ID NO: 12), h5A1002 antibody (heavy chain sequence SEQ ID NO: 13 and light chain sequence SEQ ID NO: 14), and matching IgG1 (purchased from Hyakuei Seizo) diluted with PBST gradient of 0.05% BSA (maximum working concentration 20000 ng / ml, 5-fold dilution, 8 gradient) are added, and the plate is closed by incubating at 37 ° C for 1 h. The reaction system in the wells is aspirated, and the plate is washed six times with PBST. Then, 100 μL / well of anti-human antibody secondary antibody (Fab specificity) (purchased from Sigma) marked with HRP (horseradish peroxidase) is diluted in PBST containing 0.05% BSA, and incubated at 37 °C for 1 h. The secondary antibody in the wells is aspirated and removed, and the plate is washed six times with PBST. Then, 80 μL / well of TMB (tetramethylbenzidine) is added, and the plate is incubated at room temperature for 3 min. Then, 80 μL / well of 4 M sulfuric acid is added to stop the reaction. The absorbance value at 450 mm is read on a microplate reader.
[0133] The results, as shown in Figures 3, 4, 5, 6, 7 and 8, indicate that the antibodies of the present invention can bind to MICA*002, MICA*005, MICA*008, MICA*004, MICB*001 and MICB*005, and the binding of the affinity matured antibody h5A1002 to MICA*002, MICA*005 and MICA*008 is stronger than that of the parent humanized antibody h5A1.
[0134] (2) ELISA is used to detect the binding characteristics of affinity-matured antibody h5A1002, alloantibody CLN-619 (Cullinan, the sequence is from patent US20210253711A1, prepared by the method described in Example 1), and 1D5V11 (Genentech, the sequence is from patent US20200055939A1, prepared by the method described in Example 1) with the α3 domain of MICA and MICB. The inventors coat the obtained various MICA and MICB variant extracellular region α3 domain (MICA-002, 005, 008, 004, MICB-001, 005 α3 domain) Fc fusion proteins on a 96-well plate, and the signal intensity after antibody addition is used to judge the binding characteristics of the antibody with MICA and MICB.
[0135] The experimental process is shown in step (1), and the results are shown in Figures 11, 12, 13, 14, 15 and 16, which show that the antibodies of the present invention can bind to MICA*002, MICA*005, MICA*008, MICA*004, MICB*001 and MICB*005, and the binding of the affinity matured antibody h5A1002 to MICA*002, MICA*005 and MICA*008 is stronger than that of the same target antibody CLN-619 (Cullinan).
[0136] Example 5: MICA antibody flow cytometry binding experiments
[0137] (1) 2 × 10 tumor cells in PBS 6Dilute to 100μg / mL, add to 1.5ml EP tube with a volume of 100μL / tube, add 10μL / tube of goat serum into it, and close at 4℃ for 30min. Add gradient dilution (maximum working concentration is 50μg / mL, 10 gradients, 3-fold dilution in each gradient) of h5A1 antibody (heavy chain sequence SEQ ID NO:11 and light chain sequence SEQ ID NO:12), h5A1002 antibody (heavy chain sequence SEQ ID NO:13 and light chain sequence SEQ ID NO:14), and matching IgG1 (purchased from Hyakuei Seizo) and incubate at 4℃ for 30min. Add 1mL of PBS to the EP tube, centrifuge at 3500rpm×5min at 4℃, discard the supernatant, and wash once with PBS. After centrifugation, the supernatant is discarded, the cells are resuspended in 100 μl / tube of PBS, to which 1 μL / tube of Alexa-647-marked goat anti-human antibody secondary antibody (purchased from Jackson lab) is added, and incubated at 4°C for 30 min in the dark. Wash twice with PBS, and discard all of the supernatant after centrifugation. The cells are resuspended in 200 μL / tube of PBS, and detected by a flow cytometer. The results are shown in Figures 9 and 10, which show that the binding of the affinity-matured antibody h5A1002 of the present invention to A-375 melanoma cells and HCT-15 colon cancer cells is stronger than that of the parent humanized antibody h5A1.
[0138] (2) 2 × 10 tumor cells in PBS 6Dilute to 100μg / mL, add to 1.5ml EP tube with a volume of 100μL / tube, add 10μL / tube of goat serum into it, and close at 4℃ for 30min. Add gradient dilution (maximum working concentration is 50μg / mL, 10 gradients, 3-fold dilution in each gradient) of h5A1 antibody (heavy chain sequence SEQ ID NO:13 and light chain sequence SEQ ID NO:14), CLN-619 antibody (heavy chain sequence SEQ ID NO:17 and light chain sequence SEQ ID NO:18), 1D5V11 antibody (heavy chain sequence SEQ ID NO:19 and light chain sequence SEQ ID NO:20), and matching IgG1 (purchased from Hyakuei Seizo) and incubate at 4℃ for 30min. Add 1mL of PBS to the EP tube, centrifuge at 3500rpm×5min at 4℃, discard all the supernatant, and wash once with PBS. After centrifugation, the supernatant is discarded, the cells are resuspended in 100 μl / tube of PBS, to which 1 μL / tube of Alexa-647-marked goat anti-human antibody secondary antibody (purchased from Jackson lab) is added, and incubated at 4°C for 30 min in the dark. Wash twice with PBS, and after centrifugation, the supernatant is discarded. The cells are resuspended in 200 μL / tube of PBS, and detected by a flow cytometer. The results are shown in Figures 17, 18, 19, and 20, which show that the binding of the affinity-matured antibody h5A1002 of the present invention to tumor cells A-375 melanoma cells, A-549 non-small cell lung cancer cells, HCT-15 colon cancer cells, and MDA-MB-231 breast cancer cells is stronger than that of the same target antibody CLN-619 (Cullinan).
[0139] Example 6: Epitope competition experiments
[0140] Flow cytometry was used to detect the epitope competition between affinity-matured antibody h5A1002 and the allogeneic antibodies CLN-619 (Cullinan) and 1D5V11 (Genentech).
[0141] 2 x 10 tumor cells in PBS 610 μg / mL, and add to 1.5 ml EP tubes with a volume of 100 μL / tube, add 10 μL / tube of goat serum into it, and close at 4 ° C for 30 min. Add affinity matured antibodies h5A1002 (heavy chain sequence SEQ ID NO: 13 and light chain sequence SEQ ID NO: 14), CLN-619 antibody (heavy chain sequence SEQ ID NO: 17 and light chain sequence SEQ ID NO: 18), 1D5V11 antibody (heavy chain sequence SEQ ID NO: 19 and light chain sequence SEQ ID NO: 20), and hIgG1 (purchased from Hyakuei Seizo) diluted in gradients (maximum working concentration is 300 μg / ml, 10 gradients, 3-fold dilution in each gradient) and incubate at 4 ° C for 30 min. Add the biotin-marked affinity matured antibody Biotin-h5A1002 (heavy chain sequence SEQ ID NO: 13 and light chain sequence SEQ ID NO: 14) and incubate at 4°C for 30 min. Add 1 mL of PBS to the EP tube, centrifuge at 3500 rpm x 5 min at 4°C, discard all the supernatant, and wash once with PBS. After centrifugation, discard all the supernatant, resuspend the cells in 100 μl / tube of PBS, add 1 μL / tube of Alexa-647-marked Streptavidin secondary antibody (purchased from Biolegend), and incubate at 4°C for 30 min in the dark. Wash twice with PBS, centrifuge, and discard all the supernatant. The cells were resuspended in 200 μL / tube of PBS and detected using a flow cytometer. The results are shown in Figure 21, which shows that the antigen epitopes bound by the affinity matured antibody h5A1002 of the present invention and CLN-619 (Cullinan) overlap, while h5A1002 and 1D5V11 (Genentech) bind to different antigen epitopes.
[0142] Example 7: MICA antibody endocytosis experiments
[0143] The affinity-matured antibody h5A1002 and the homologous antibodies CLN-619 (Cullinan) and 1D5V11 (Genentech) were labeled with pHrodo (purchased from Thermo) and added to the cell culture system. After 24 h of incubation, cellular fluorescence was detected. The intensity of the fluorescent signal reflected the status of antibody endocytosis.
[0144] 1 x 10 MDA-MB-231 cells in PBS 5 100 μg / mL, and then added to a 96-well plate in a volume of 200 μL / well, into which were added gradient-diluted (the highest working concentration is 50 μg / mL, 10 gradients, 3-fold dilution in each gradient) h5A1002-pHrodo (heavy chain sequence SEQ ID NO:13 and light chain sequence SEQ ID NO:14), CLN-619-pHrodo (heavy chain sequence SEQ ID NO:17 and light chain sequence SEQ ID NO:18), and 1D5V11-pHrodo (heavy chain sequence SEQ ID NO:19 and light chain sequence SEQ ID NO:20), and incubated at 37° C. and 5% CO2 for 24 h, and then detected antibody endocytosis by flow cytometry. The results are shown in FIG. 22, which shows that the endocytosis of the affinity-matured antibody h5A1002 of the present invention is weaker than that of the homologous antibodies CLN-619 and 1D5V11, which indicates better drug discovery potential of monoclonal antibodies.
[0145] Example 8: MICA antibody enhances PBMC killing of tumor cells
[0146] To detect the ability of MICA monoclonal antibody to promote killing of PBMCA-375 melanoma cells and HCT-15 colon cancer cells. (1) Add complete RPMI-1640 medium to a 16-well RTCA plate at a volume of 50 μL / well and calibrate the instrument. (2) 2 × 10 tumor cells in complete RPMI-1640 medium 5 1 / mL and added independently to the RTCA plate obtained in step (1) at a volume of 50 μL / well, and then the cell count is detected for 24 h using a xCELLigence RTCA MP instrument under conditions of 37° C. and 5% CO2. (3) h5A1002 (heavy chain sequence SEQ ID NO:13 and light chain sequence SEQ ID NO:14), h5A1002-hIgG1LALA (prepared by the method described in Example 1; heavy chain sequence SEQ ID NO:15 and light chain sequence SEQ ID NO:14), h5A1002-hIgG1DLE (prepared by the method described in Example 1; heavy chain sequence SEQ ID NO:16 and light chain sequence SEQ ID NO:14), CLN-619 antibody (heavy chain sequence SEQ ID NO:17 and light chain sequence SEQ ID NO:18), 1D5V11 antibody (heavy chain sequence SEQ ID NO:19 and light chain sequence SEQ ID NO:20), and 1D5V11 antibody (heavy chain sequence SEQ ID NO:21 and light chain sequence SEQ ID NO:22) in complete RPMI-1640 medium. NO:20), and dilute hIgG1 (purchased from Hyakuei Seibutsu) with a gradient (the highest concentration in Figure 23 is 10 μg / ml, with 8 gradients, diluted 3-fold in each gradient; the highest concentration in Figures 24 and 25 is 50 μg / ml, with 12 gradients, diluted 5-fold in each gradient), and add to the RTCA plate obtained in step (2), with an addition volume of 20 μL / well. (4) 1.25 × 10 PBMCs (purchased from Myojun Biology) in complete RPMI-1640 medium 6 The mixture is diluted to 500 μl / mL and added to the RTCA plate obtained in step (3) with an addition volume of 80 μL / well. (5) The reaction system obtained in step (4) was subjected to cell count detection for 24 hours using an xCELLigence RTCA MP device at 37°C and 5% CO2.
[0147] As shown in FIG. 23, the MICA antibody of the present invention promotes tumor killing by PBMCs, and the hIgG1 subtype antibody h5A1002, the ADCC-deprived antibody h5A1002-hIgG1LALA, and the ADCC-enhanced antibody h5A1002-hIgG1DLE all have the promoting function.
[0148] As shown in Figures 24 and 25, the h5A1002 antibody of the present invention promotes tumor killing by PBMCs, and the killing-promoting function of the hIgG1 subtype antibody (h5A1002) is superior to that of the same targeting antibody CLN-619 (also of hIgG1 subtype), with the ADCC-enhancing antibody h5A1002-hIgG1DLE having the strongest promoting function, stronger than all other antibodies.
[0149] In the present specification, the reference words such as "one embodiment", "some embodiments", "examples", "specific examples", or "some examples" mean that the specific features, structures, materials, or characteristics described in the embodiment or example are included in at least one embodiment or example of the present invention. In the present specification, the above-mentioned terms and exemplary descriptions do not necessarily refer to the same embodiment or example. In addition, the specific features, structures, materials, or characteristics described can be combined in an appropriate manner in one or more embodiments or examples. Furthermore, if not in conflict with each other, a person skilled in the art can combine different embodiments or examples and features of different embodiments or examples described in the present specification.
[0150] Although embodiments of the present invention have been presented and described, the above embodiments are illustrative and should not be construed as limiting the present invention. Those skilled in the art will appreciate that various changes, modifications, substitutions and variations are possible in the above embodiments within the scope of the present invention.
Claims
1. An antibody or antigen-binding fragment thereof, heavy chain variable region CDR1, CDR2, CDR3 sequences shown in SEQ ID NO: 1, 2 and 3 or amino acid sequences having at least 80% identity with SEQ ID NO: 1, 2 and 3, respectively; and a light chain variable region CDR1, CDR2, CDR3 sequence represented by an amino acid sequence having at least 80% identity with SEQ ID NO: 4, 5, and 6, respectively.
2. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that it comprises a heavy chain variable region CDR1 sequence shown in SEQ ID NO: 1, a heavy chain variable region CDR2 shown in SEQ ID NO: 2, a heavy chain variable region CDR3 shown in SEQ ID NO: 3, a light chain variable region CDR1 shown in SEQ ID NO: 4, a light chain variable region CDR2 shown in SEQ ID NO: 5, and a light chain variable region CDR3 shown in SEQ ID NO:
6.
3. The antibody or antigen-binding fragment thereof according to claim 1 , wherein the antibody or antigen-binding fragment thereof specifically recognizes MICA.
4. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that the antibody comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region being shown in SEQ ID NO: 7, and the amino acid sequence of the light chain variable region being shown in SEQ ID NO:
8.
5. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody is a humanized antibody.
6. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that the antibody or antigen-binding fragment thereof comprises a heavy chain framework region sequence and a light chain framework region sequence, and at least a portion of at least one of the heavy chain framework region sequence and the light chain framework region sequence is derived from at least one of a mouse-derived antibody, a human-derived antibody, a primate-derived antibody or a variant thereof.
7. the antibody or antigen-binding fragment thereof comprises at least one of a heavy chain constant region and a light chain constant region, and at least a portion of at least one of the heavy chain constant region and the light chain constant region is derived from at least one of a human-derived antibody, a primate-derived antibody, and a mouse-derived antibody or a variant thereof; The antibody or antigen-binding fragment thereof according to claim 1, characterized in that, optionally, the light chain constant region and the heavy chain constant region are both derived from a mouse-derived IgG1 antibody, an IgG2a antibody or a mutant thereof, or a human-derived IgG1 antibody, an IgG2 antibody, an IgG3 antibody, an IgG4 antibody or a mutant thereof.
8. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that the antibody or antigen-binding fragment thereof is at least one of a single chain antibody, a multimeric antibody, a CDR-grafted antibody, a Fab antibody, and an Fv antibody.
9. A nucleic acid molecule, characterized in that the nucleic acid molecule encodes an antibody or antigen-binding fragment thereof according to any one of claims 1 to 8.
10. An expression vector, comprising the nucleic acid molecule of claim 9.
11. A method for preparing the antibody or antigen-binding fragment thereof according to any one of claims 1 to 8, comprising the steps of: introducing into a cell an expression vector carrying a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof; and culturing the cells under conditions suitable for protein expression and secretion to obtain the antibody or antigen-binding fragment thereof. Optionally, the cell is a prokaryotic or eukaryotic cell; Optionally, the cell is a eukaryotic cell.
12. A recombinant cell, characterized in that the recombinant cell expresses the antibody or antigen-binding fragment thereof according to any one of claims 1 to 8.
13. 1. A composition comprising: A composition comprising an antibody or an antigen-binding fragment thereof according to any one of claims 1 to 8.
14. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 8 in the preparation of a medicament for preventing and / or treating a MICA-mediated disease.
15. said MICA mediated disease is cancer; Optionally, the cancer is at least one of lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, renal cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, and head and neck cancer.
16. A drug comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 8, which is used for preventing and / or treating a MICA-mediated disease.
17. said MICA mediated disease is cancer; Optionally, the cancer is at least one of lung cancer, liver cancer, ovarian cancer, cervical cancer, skin cancer, bladder cancer, colon cancer, breast cancer, glioma, renal cancer, gastric cancer, esophageal cancer, oral squamous cell carcinoma, and head and neck cancer.
18. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1 to 8 in the preparation of a reagent kit for detecting MICA.
19. A reagent kit comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 8.
Citation Information
Patent Citations
Antibodies and uses thereof
CN114369162A
